Targets › HSV2
2 programs from 2 companies in 2 trials: 1 Phase 4, 1 Phase 1; Immunology, Infectious disease; next expected readout Apr 2027.
Open in Phaseline: the race on HSV2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Sao Paulo General Hospital | Acyclovir Human herpesvirus 1 DNA polymerase inhibitor | HSV1, HSV2, VZV | Phase 4 | Autoimmune Rheumatic Diseases | Apr 2027 |
| BioNTech SE | BNT163 Anti-viral RNA vaccine for active immunization against HSV-2 | HSV2 | Phase 1 | Genital Herpes Simplex Type 2 | – |
Autoimmune Rheumatic Diseases (1) Genital Herpes Simplex Type 2 (1)
small molecule (1), protein or peptide (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.